Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Orally efficacious NR2B-selective NMDA receptor antagonists.

Christopher F Claiborne1, John A McCauley, Brian E Libby

  • 1Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA.

Bioorganic & Medicinal Chemistry Letters
|March 18, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Physiologically-Based Pharmacokinetic Model to Characterize Dasotraline Pharmacokinetics and CYP-mediated Drug-Drug Interactions.

Drug metabolism and bioanalysis letters·2026
Same author

A brief visual evoked potential (VEP) modulation assessment of experience-dependent plasticity recorded via wireless dry-EEG headset in Phase 1 clinical units.

Scientific reports·2026
Same author

MK-7602: a potent multi-stage dual-targeting antimalarial.

EBioMedicine·2025
Same author

Estimating heterogeneity of treatment effect in psychiatric clinical trials.

Journal of psychiatric research·2025
Same author

Structure-activity analysis of imino-pyrimidinone-fused pyrrolidines aids the development of dual plasmepsin V and plasmepsin X inhibitors.

The FEBS journal·2025
Same author

Highly Diastereoselective Access to Densely Functionalized Piperidine Cores of Influenza Endonuclease Inhibitors via a Metal-Free S<sub>N</sub>1 Approach.

The Journal of organic chemistry·2025

Novel benzamidines act as selective NMDA receptor antagonists. Compound 31 effectively reduces pain in rats without causing motor coordination issues, indicating therapeutic potential.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Medicinal Chemistry

Background:

  • NMDA receptors are implicated in pain signaling.
  • NR2B-subtype selectivity is a target for developing safer analgesics.
  • Benzamidines represent a potential class of NMDA receptor antagonists.

Purpose of the Study:

  • To synthesize and evaluate a novel series of benzamidines for NR2B-subtype selective NMDA antagonist activity.
  • To assess the in vivo efficacy and safety of lead compounds in a preclinical pain model.

Main Methods:

  • Synthesis of a novel benzamidine series.
  • In vitro assessment of NMDA receptor antagonist activity, focusing on NR2B-subtype selectivity.
  • In vivo evaluation of Compound 31 in a carrageenan-induced hyperalgesia rat model.

Related Experiment Videos

  • Behavioral testing for motor coordination side effects.

    • Main Results:

    • The synthesized benzamidines demonstrated NR2B-subtype selective NMDA antagonist activity.
    • Compound 31 exhibited oral activity in the carrageenan-induced hyperalgesia model.
    • Compound 31 did not produce motor coordination side effects in the tested model.

    Conclusions:

    • The novel benzamidine series holds promise as NR2B-selective NMDA antagonists.
    • Compound 31 is a promising candidate for further development as an orally active analgesic with an improved safety profile.